Activation of the ERK1/2 pathway has been implicated in the mechanisms underlying cerebral ischemia, i.e., decreased lesion volumes have been demonstrated following the administration of specific inhibitors (Irving et al., 2000; Irving and Bamford, 2002). The gene discussed is MAPK3; the disease is brain ischemia.